Search

everythinglearnresearchcommunity

for

Search:↓

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

42% of SLE patients had thyroid issues, mostly hypothyroidism.

Good medication adherence improves quality of life in subclinical thyroid disorder patients.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

A cream with a specific hormone blocker increases hair growth in mice.

TSC2-/meth cells can cause skin lesions, hair growth, and lung issues, and may be treated with chromatin remodeling agents.

Steroid sulfatase inhibitors could help treat hormone-related disorders and cancers.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Topical thyroid hormones may boost hair growth.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

The treatment was not recommended due to limited effectiveness and significant side effects.

Anti-TNF therapy can cause a rare hair loss condition similar to alopecia areata.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

3-tetrazolo steroidal analogs can strongly inhibit the enzyme linked to hair loss.

Block and replace therapy improved symptoms in recurrent cyclic Cushing’s disease.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.